STOCK TITAN

BioAffinity Technologies Inc - BIAFW STOCK NEWS

Welcome to our dedicated news page for BioAffinity Technologies (Ticker: BIAFW), a resource for investors and traders seeking the latest updates and insights on BioAffinity Technologies.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect BioAffinity Technologies's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of BioAffinity Technologies's position in the market.

Rhea-AI Summary
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW) announced the appointment of Jamie Platt, Ph.D., to its Board of Directors, effective Dec. 1, 2023. Dr. Platt brings two decades of experience in diagnostic technologies and has been instrumental in two M&A exits for diagnostic companies in 2022, resulting in a combined value of nearly $1 billion. She has extensive experience in expanding product market share in the diagnostics market. Dr. Platt's appointment is expected to drive bioAffinity's growth and success, particularly in commercializing CyPath® Lung, their noninvasive test for the early detection of lung cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.81%
Tags
management
-
Rhea-AI Summary
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW) announced that the Centers for Medicare and Medicaid Services (CMS) has made a final determination for payment for CyPath® Lung, a noninvasive test for early-stage lung cancer, for the 2024 calendar year. The CMS payment determination is a major milestone that facilitates reimbursement by both Medicare and private payers, making the test more attractive to physicians and their patients at high risk for lung cancer. The test showed 92% sensitivity, 87% specificity, and 88% accuracy in detecting lung cancer in patients with small lung nodules less than 20 millimeters.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
22.96%
Tags
none
-
Rhea-AI Summary
BioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW) announced that David Elzi, Ph.D., has been named to the Membership Committee of the American Society for Cell Biology (ASCB). ASCB is an international organization of cell biologists dedicated to advancing scientific discovery and improving education. Dr. Elzi will host a roundtable at Cell Bio 2023 to discuss transferable skills for transitioning into the biotech industry.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.35%
Tags
none
Rhea-AI Summary
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW) launches a campaign with the American Cancer Society to increase lung cancer screening in Texas. The 'Power of Three' campaign aims to support local programs and emphasizes the importance of joining forces in the fight against lung cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.8%
Tags
none
-
Rhea-AI Summary
BIAF - bioAffinity Technologies, Inc. reported financial results for the third quarter of 2023 and provided a business update. The company's subsidiary acquired Village Oaks Pathology Services, and CMS released a preliminary payment decision for CyPath® Lung. The U.S. Department of Defense purchased CyPath® Lung tests for an observational study. Revenue for the third quarter of 2023 increased to $298,484, and net loss was $2.3 million. The company expects to generate between $2.1 and $2.3 million in net revenues for 2023 and between $8.4 and $9.0 million over the next 12 months.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.8%
Tags
earnings
-
Rhea-AI Summary
bioAffinity Technologies, Inc. has appointed Dallas J. Coleman as National Director of Sales. Coleman has over 15 years of experience in medical sales and marketing. He will be responsible for leading the CyPath® Lung sales team and sourcing new business opportunities. His expertise is expected to help drive the expansion of their pilot market launch across Texas and pave the way for the national rollout of CyPath® Lung.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.04%
Tags
none
Rhea-AI Summary
bioAffinity Technologies, Inc. CEO Maria Zannes to present corporate update at Dawson James Small Cap Growth Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.27%
Tags
conferences
-
Rhea-AI Summary
bioAffinity Technologies acquires Precision Pathology Services to support commercialization of CyPath® Lung test. The acquisition cost $3.5 million in cash and stock. The transaction aims to accelerate market uptake, support FDA pivotal trial, and develop additional tests. Precision Pathology offers a range of laboratory services. Dr. Roby Joyce joins bioAffinity's board of directors. Conference call at 4:30 p.m. ET today.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.63%
Tags
acquisition
-
Rhea-AI Summary
bioAffinity Technologies to present corporate update and hold meetings with investors at H.C. Wainwright conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.58%
Tags
conferences
Rhea-AI Summary
bioAffinity Technologies reports financial results for Q2 2023 and provides business update
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.27%
Tags
earnings
BioAffinity Technologies Inc

Nasdaq:BIAFW

BIAFW Rankings

BIAFW Stock Data

5.97M
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States
San Antonio

About BIAFW

addressing a critical need to find cancer early and treat cancer specifically bioaffinity technologies, inc. develops tests and therapies to detect and treat cancer at the cellular level. our first product, cypath® flow cytometry for lung cancer (cypath® lung), has been licensed by precision pathology services for continued development and commercial sale as a laboratory developed test. cypath® lung has the potential to dramatically increase overall diagnostic accuracy leading to increased survival, fewer unnecessary invasive procedures and lower patient anxiety and medical costs.